Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial

Characterization of HIV infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083

(2021) Mark A Marzinke et al.   JOURNAL OF INFECTIOUS DISEASES

Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition

(2021) Lawrence Corey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults

(2021) Glenda E. Gray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

(2021) Raphael J. Landovitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

The influence of HIV‐related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study

(2020) Jennifer Velloza et al.   Journal of the International AIDS Society

Factors influencing uptake, continuation, and discontinuation of oral PrEP among clients at sex worker and MSM facilities in South Africa

(2020) Diantha Pillay et al.   PLoS One

Young women’s stated preferences for biomedical HIV prevention

(2019) Alexandra M. Minnis et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Cabotegravir is Not Associated with Weight Gain in HIV-uninfected Individuals in HPTN 077

(2019) Raphael J Landovitz et al.   CLINICAL INFECTIOUS DISEASES

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

(2019) Willem D.F. Venter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial

(2018) Raphael J. Landovitz et al.   PLOS MEDICINE

Divergent Preferences for HIV Prevention: A Discrete Choice Experiment for Multipurpose HIV Prevention Products in South Africa

(2017) Matthew Quaife et al.   MEDICAL DECISION MAKING

Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial

(2017) Martin Markowitz et al.   Lancet HIV

Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066)

(2016) Craig W. Hendrix et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

An Empiric HIV Risk Scoring Tool to Predict HIV-1 Acquisition in African Women

(2016) Jennifer E. Balkus et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine

(2016) Mackenzie L. Cottrell et al.   JOURNAL OF INFECTIOUS DISEASES

Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women

(2015) Jeanne M. Marrazzo et al.   NEW ENGLAND JOURNAL OF MEDICINE

The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge

(2015) J. Radzio et al.   Science Translational Medicine

A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge

(2015) Chasity D. Andrews et al.   Science Translational Medicine

HIV Protective Efficacy and Correlates of Tenofovir Blood Concentrations in a Clinical Trial of PrEP for HIV Prevention

(2014) Deborah Donnell et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Tenofovir, Emtricitabine, and Tenofovir Diphosphate in Dried Blood Spots for Determining Recent and Cumulative Drug Exposure

(2012) Jose R. Castillo-Mancilla et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES